Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Eye cancer, intraocular melanoma
Stage/Subtype:  metastatic intraocular melanoma
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active
Results 1-12 of 12 for your search:
Start Over
Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 10-154, NCT01223248
Ipilimumab for Uveal Melanoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2011-0919, NCI-2012-00665, NCT01585194
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: 05-122, MSKCC-05122, NCT00445965
RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 10-123, NCT01252251
SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 10D.95, NCT01473004
Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: BMS CA184-168, NCT01565837
Vorinostat in Treating Patients With Metastatic Melanoma of the Eye
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-00860, MSKCC-12-027, CDR0000732297, 12-027, 9111, N01CM62206, P30CA008748, U01CA069856, UM1CA186689, NCT01587352
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: NCI
Protocol IDs: 130093, 13-C-0093, NCT01814046
Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2013-02091, 13-144, 9445, N01CM00039, P30CA008748, NCT01979523
CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301in Treating Patients With Stage IIB-IV Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2014-00898, CITN-07-FLT3L, U01CA154967, NCT02129075
Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 to 90
Sponsor: Pharmaceutical / Industry
Protocol IDs: POLARIS2012-005, NCT01665183
Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy
Phase: No phase specified
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: MEL0005, SU-08242011-8306, 21970, NCT01449279
Start Over